Sigyn Therapeutics (SIGY) Receivables (2017 - 2020)

Sigyn Therapeutics (SIGY) posted Receivables of $756.0 for Q1 2020, down 31.4% sequentially from $1102.0 in Q3 2018.

Sigyn Therapeutics (SIGY) Receivables (2017 - 2020) Analysis & Trends

Sigyn Therapeutics has reported Receivables for 3 years, with the latest figure at $756.0 in Q1 2020.

Quarterly Receivables changed N/A year-over-year to $756.0 in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $756.0 (changed N/A YoY) and the FY2017 annual result came in at $9730.0, changed N/A from the prior year.
Receivables declined to $756.0 in Q1 2020 per SIGY's latest filing, from $1102.0 in the prior quarter.
Over five years, Receivables peaked at $63002.0 in Q2 2017 and troughed at $756.0 in Q1 2020.
A 3-year average of $17899.5 and a median of $13526.0 in 2017 frame the typical range for Receivables.
The widest YoY moves for Receivables: up 8.01% in 2018, down 95.22% in 2018.
Over 3 years, Receivables stood at $9730.0 in 2017, then sank by 88.67% to $1102.0 in 2018, then plunged by 31.4% to $756.0 in 2020.
According to Business Quant data, Receivables over the past three periods registered $756.0, $1102.0, and $3013.0 for Q1 2020, Q3 2018, and Q2 2018 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.93 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	912.74 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	215.33 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.09 Bn
10	Sigyn Therapeutics	48,161.31	-37,409.69	-	-

Download Data